Noticias de SVRA_US

Noticias del mercado

Últimas noticias sobre SVRA_US — 133 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SVRA_US ✕ 133 resultados
18/04/2026 SVRA_US — Kalkine Media
Savara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech Segment
17/04/2026 SVRA_US — Bluefield Daily Telegraph
Savara Announces New Employment Inducement Grant
17/04/2026 SVRA_US — Business Wire
Savara Announces New Employment Inducement Grant
17/04/2026 SVRA_US — simplywall.st
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP
17/04/2026 SVRA_US — MarketBeat
Savara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's Why
17/04/2026 SVRA_US — DirectorsTalk Interviews
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 91.71% Potential Upside
17/04/2026 SVRA_US — Yahoo Finance
Savara Announces New Employment Inducement Grant
16/04/2026 SVRA_US — GuruFocus ES ← EN
Savara (SVRA) recibe una extensión de revisión de la FDA para la aplicación Molgramostim
16/04/2026 SVRA_US — GuruFocus ES ← EN
Savara (SVRA) recibe una extensión de tres meses para la revisión de BLA
16/04/2026 SVRA_US — BioSpace
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune…

16/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application By Investing.com
16/04/2026 SVRA_US — Seeking Alpha
Savara gets FDA review extension for lead asset (SVRA:NASDAQ)
16/04/2026 SVRA_US — GuruFocus
Savara (SVRA) Receives FDA Review Extension for Molgramostim App
15/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application By Investing.com
15/04/2026 SVRA_US — BioSpace
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
15/04/2026 SVRA_US — Yahoo Finance
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune…

15/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application
15/04/2026 SVRA_US — Stocktwits
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy
15/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application By Investing.com
15/04/2026 SVRA_US — ChartMill
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune…

Página 4 de 7

keyboard_arrow_up